Insider · CIK 0001756941
Christina Rossi
cooofficerdirector
Files at BPMC (Blueprint Medicines Corp), XLO (Xilio Therapeutics, Inc.), CGON (CG Oncology, Inc.). First filing Dec 2, 2024, latest Jul 8, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 9
$0 bought, $2.3M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | Blueprint Medicines Corp | $150k 1,172 shares | -2% | - | |
| 28Weak | Blueprint Medicines Corp | $229k 2,274 shares | -3% | - | |
| 21Weak | Blueprint Medicines Corp | $231k 2,274 shares | -3% | - | |
| 27Weak | Blueprint Medicines Corp | $216k 2,274 shares | -3% | - | |
| 54Moderate | Blueprint Medicines Corp | $577k 6,495 shares | -8% | - | |
| 27Weak | Blueprint Medicines Corp | $216k 2,274 shares | -3% | - | |
| 28Weak | Blueprint Medicines Corp | $250k 2,274 shares | -3% | - | |
| 27Weak | Blueprint Medicines Corp | $218k 2,274 shares | -3% | - | |
| 27Weak | Blueprint Medicines Corp | $216k 2,274 shares | -3% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 24, 2025 | CGON CG Oncology, Inc. | AGrant or award Director Stock Option (right to buy)derivative10b5-1 | +20,889 | $0.00 | $0 | 20,889 | Nov 26, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | AGrant or award Common Stock | +39,456 | - | - | 103,002 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Common Stock | -82,374 | - | - | 20,628 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | UTender of shares Common Stock | -20,628 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -6,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -26,125 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -30,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -30,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -30,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -26,400 | - | - | 0 | Jul 21, 2025 |
| Jul 3, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock | -1,172 | $128.25 | $150k | 63,546 | Jul 8, 2025 |
| Jun 11, 2025 | XLO Xilio Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +31,000 | $0.00 | $0 | 31,000 | Jun 12, 2025 |
| May 19, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -804 | $100.14 | $81k | 66,188 | May 21, 2025 |
| May 19, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -1,413 | $100.67 | $142k | 64,775 | May 21, 2025 |
| May 19, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -57 | $101.72 | $5,798 | 64,718 | May 21, 2025 |
| May 5, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -607 | $100.97 | $61k | 68,659 | May 7, 2025 |
| May 5, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -1,343 | $101.77 | $137k | 67,316 | May 7, 2025 |
| May 5, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -180 | $102.82 | $19k | 67,136 | May 7, 2025 |
| May 5, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -144 | $103.56 | $15k | 66,992 | May 7, 2025 |
| Mar 24, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -2,274 | $95.02 | $216k | 69,266 | Mar 26, 2025 |
| Mar 5, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock | -6,495 | $88.80 | $577k | 71,540 | Mar 7, 2025 |
| Mar 1, 2025 | BPMC Blueprint Medicines Corp | AGrant or award Common Stock | +13,200 | $0.00 | $0 | 78,035 | Mar 4, 2025 |
| Mar 1, 2025 | BPMC Blueprint Medicines Corp | AGrant or award Stock Option (Right to Buy)derivative | +26,400 | $0.00 | $0 | 26,400 | Mar 4, 2025 |
| Feb 20, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -2,274 | $95.14 | $216k | 64,835 | Feb 24, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -529 | $108.99 | $58k | 68,854 | Jan 23, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -816 | $110.00 | $90k | 68,038 | Jan 23, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -808 | $110.78 | $90k | 67,230 | Jan 23, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -121 | $111.81 | $14k | 67,109 | Jan 23, 2025 |
| Dec 18, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -2,166 | $95.88 | $208k | 69,491 | Dec 20, 2024 |
| Dec 18, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -108 | $96.50 | $10k | 69,383 | Dec 20, 2024 |
| Nov 27, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -2,274 | $95.10 | $216k | 71,657 | Dec 2, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.